Related references
Note: Only part of the references are listed.An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
Ayodele Ayoola et al.
CANCER INVESTIGATION (2012)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Michael S. Glickman et al.
CELL (2012)
Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng et al.
CLINICAL CANCER RESEARCH (2012)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Kang-Yi Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair
Xue Zhang et al.
NATURE GENETICS (2012)
In cancer drug resistance, germline matters too
Emily H. Cheng et al.
NATURE MEDICINE (2012)
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan et al.
CANCER DISCOVERY (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
ZEB1-responsive genes in non-small cell lung cancer
Robert M. Gemmill et al.
CANCER LETTERS (2011)
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
Marianne E. Marshall et al.
CLINICAL CANCER RESEARCH (2011)
Synthesis and Structure-Affinity Relationships of Novel Dibenzylideneacetone Derivatives as Probes for β-Amyloid Plaques
Mengchao Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
Alexis Mollard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Drugging Drug Resistance
Jan-Hermen Dannenberg et al.
CELL (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
Kathryn E. Ware et al.
PLoS One (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
Scott A. Kono et al.
DRUG RESISTANCE UPDATES (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Lindsay Marek et al.
MOLECULAR PHARMACOLOGY (2009)
EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
Lecia V. Sequist et al.
ANNUAL REVIEW OF MEDICINE (2008)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
Atsuko Ogino et al.
CANCER RESEARCH (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Barbara A. Frederick et al.
MOLECULAR CANCER THERAPEUTICS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells totreatment with gefitinib
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2006)
RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation
LA McDermott et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
The role of surgery in N2 non-small cell lung cancer
MM DeCamp et al.
CLINICAL CANCER RESEARCH (2005)
Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer
C Müller-Tidow et al.
CANCER RESEARCH (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)